A new report from Markets and Markets predicts that the global blood culture market will reach around $3.473 billion by 2019, growing at a CAGR of around 6.8% during the forecast period (2014 to 2019).
Blood culture tests detect the presence of bacteria or fungi blood that lead to infection. The culture can show what type of germ is causing the infection so that physicians can determine the best course of treatment. The test can also check for endocarditis, which is an infection of the valves of the heart. Modern blood culture systems are designed to provide highly accurate and timely results and come with advanced features such as
- Vial-activated workflow
- Advanced ergonomics
- Remote alarm
- Blood culture observation capability
- Customer-focused data management
The Markets and Markets report segments the market on the basis of methods, products, applications, end users, and regions. Key factors driving the growth of the blood culture test market include
- Increase in blood stream infections (BSI)
- Rising demand for rapid diagnostic techniques
- High prevalence of infectious diseases
- Increase in healthcare expenditure
- Rise in aging population
The report lists the key players in the market as bioMérieux SA (France), Becton, Dickinson and Company (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Roche Diagnostics (Switzerland), Siemens AG (Germany), Bruker Corporation (U.S.), Cepheid (U.S.), Alere, Inc. (U.S.), Abbott Laboratories (U.S.), and Nanosphere, Inc. (U.S.). Product-wise, the market is divided into consumables and instruments. On the basis of region, North America accounts for the largest share of this market.